Axsome Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
AXSM Nasdaq 2830 www.axsome.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Axsome Therapeutics, Inc.

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month - Jun 20th, 2025 5:00 am
Axsome Therapeutics, Inc. (NASDAQ:AXSM): When Will It Breakeven? - Jun 18th, 2025 5:28 am
Axsome Therapeutics to Present Data Spanning the SYMBRAVO® (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) - Jun 18th, 2025 5:00 am
Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders - Jun 16th, 2025 5:00 am
Axsome’s AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley - Jun 11th, 2025 5:57 pm
Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 - Jun 11th, 2025 5:00 am
Axsome Therapeutics Announces Availability of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults - Jun 10th, 2025 5:00 am
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia - Jun 9th, 2025 5:00 am
Axsome Therapeutics to Participate in Upcoming Investor Conferences - May 29th, 2025 5:00 am
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting - May 28th, 2025 5:00 am
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd. - May 27th, 2025 5:00 am
3 High-Flying Stocks That Could Soar Even More - May 24th, 2025 4:40 am
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone - May 13th, 2025 5:00 am
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years - May 12th, 2025 5:08 am
3 Monster Stocks in the Making - May 11th, 2025 9:15 am
Analysts Are Updating Their Axsome Therapeutics, Inc. (NASDAQ:AXSM) Estimates After Its First-Quarter Results - May 8th, 2025 4:22 am
Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... - May 6th, 2025 1:02 am
Q1 2025 Axsome Therapeutics Inc Earnings Call - May 5th, 2025 10:24 pm
The three-year returns have been enviable for Axsome Therapeutics (NASDAQ:AXSM) shareholders despite underlying losses increasing - May 5th, 2025 7:12 am
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - May 5th, 2025 5:00 am